Industry: Healthcare
Published Date: January-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 210
Report ID: PMRREP33853
The global Blood Screening market is forecasted to expand at a CAGR of 8.5% and thereby increase from US$2.22 Bn in 2023 to US$3.94 Bn by the end of 2030.
|
Attributes |
Key Insights |
|
Blood Screening Market Size (2023E) |
US$2.22 Bn |
|
Projected Market Value (2030F) |
US$3.94 Bn |
|
Global Market Growth Rate (CAGR 2023 to 2030) |
8.5% |
|
Historical Market Growth Rate (CAGR 2018 to 2022) |
7.2% |
|
Revenue Share of Top Four Countries (2022E) |
45% |
Blood screening is the systematic examination of a blood sample to detect and classify a wide range of pathological states, infections, and conditions. It entails the examination of various components, including antibodies, antigens, and other markers, to evaluate an individual's overall health. This diagnostic methodology is of the utmost importance for disease monitoring, blood transfusion safety, and preventive healthcare. Blood screening plays a crucial role in laboratories, hospitals, and blood banks as it enables the timely identification of blood-borne illnesses such as HIV, hepatitis, and others. This information enables public health measures and opportune medical intervention.
Multiple factors contribute to the expansion of the worldwide blood screening market. Key contributors include technological advances in screening methods, the rising prevalence of infectious diseases, and the rising demand for blood transfusions. Furthermore, the expansion of the market is propelled by stringent regulatory frameworks that prioritize blood safety, an increasing recognition of the critical nature of early disease detection, and the development of healthcare infrastructure in emerging economies. The ongoing advancement of novel screening techniques, in conjunction with the growing emphasis on personalized medicine, serves to drive the blood screening industry forward.
Infusion of Cutting-Edge Technological Developments in Screening Techniques
A significant factor propelling the expansion of the worldwide blood screening industry is the constant infusion of cutting-edge technological developments in screening techniques. With the continuous advancement of technology, blood screening methods have experienced substantial changes that have resulted in improved diagnostic precision, sensitivity, and efficiency. The discipline has undergone a significant transformation with the advent of molecular and genetic testing methods, including nucleic acid testing (NAT), which has facilitated the precise identification of viral and bacterial infections. NAT enables the direct identification of pathogen genetic material, thereby significantly shortening the detection window for infections such as hepatitis and HIV and thereby enhancing blood safety.
In addition, the incorporation of robotics and automation into blood screening procedures has optimized workstreams, reduced the occurrence of human errors, and increased output. Automated screening systems not only accelerate the screening process but also contribute to the cost-effectiveness of large-scale diagnostic environments, such as clinical laboratories and blood banks. Emerging technologies, including next-generation sequencing (NGS), have significantly broadened the parameters of blood screening through the ability to analyze numerous pathogens concurrently within a solitary test. The capability to multiplex improves diagnostic efficacy and facilitates the comprehensive profiling of diseases. Moreover, progress in point-of-care testing (POCT) devices provides expedited and decentralized screening alternatives, thereby enhancing the accessibility of diagnostics in locations with limited resources or remote locations. In addition to enhancing the precision and efficacy of blood screening, these technological developments also resolve issues associated with conventional techniques. The continuous pursuit of research and development in this domain is centered around the enhancement of current technologies and the implementation of innovative methodologies to address the ever-changing requirements of the healthcare sector.
Regulatory Obstacles and Rigorous Compliance Mandates
The global blood screening market is substantially limited by the complex network of regulatory obstacles and rigorous compliance mandates. Due to the critical nature of public health and safety concerns within the blood screening industry, stringent standards are enforced by regulatory bodies across the globe to guarantee the dependability and efficacy of screening procedures. Successfully navigating these regulatory frameworks requires market participants to allocate significant amounts of time and resources. The process of complying with dynamic regulations and acquiring the required approvals for emerging technologies can be protracted and intricate, resulting in the postponement of the commercialization of innovative screening solutions. The regulatory environment introduces an additional stratum of intricacy due to its ever-changing nature. Ongoing modifications in compliance criteria, standards, and guidelines require industry participants to consistently adjust their approaches, which in turn results in escalated operational expenditures.
Continuous Pandemic Preparedness Requirements
Continuous pandemic preparedness requirements and the persistent threat posed by emergent infectious diseases constitute a formidable obstacle for the global blood screening market. As outbreaks such as Zika, Ebola, and the current difficulties presented by the COVID-19 pandemic illustrate, the unpredictability of novel pathogens highlights the susceptibility of blood supplies to infectious agents. The increased risk of transfusion-transmissible infections necessitates heightened vigilance in blood screening protocols to promptly identify and mitigate emergent threats. The development and validation of specific screening tests are frequently required due to the rapid emergence of novel infectious diseases; this adds time and complexity to the blood screening procedure.
Increasing Demand for Transfusion and Blood Services on an International Scale
An advantageous factor propelling the global blood screening market is the increasing demand for transfusion and blood services on an international scale. As populations increase and healthcare systems undergo expansion, the demand for blood-related medical interventions, including cancer treatments, trauma care, and surgical procedures, also escalates. The increased level of demand for blood positions blood screening as a critical measure to guarantee the sufficiency and safety of the blood supply. The escalating incidence of chronic illnesses, in conjunction with an expanding elderly demographic, contributes to a greater prevalence of conditions necessitating blood transfusions, thereby augmenting the overall demand for compatible and screened blood units.
Furthermore, the proliferation of healthcare infrastructure in developing countries is a significant determinant in intensifying the demand for streamlined blood screening services. Concurrently with the accelerated development of these regions, healthcare accessibility and awareness increase, resulting in a greater demand for blood screening to support a variety of medical procedures. This provides blood screening companies with a favorable market environment in which to establish a foothold in these rapidly expanding sectors. Furthermore, the worldwide emphasis on fortifying healthcare systems, particularly in the aftermath of public health emergencies, emphasizes the criticality of implementing rigorous blood screening protocols to safeguard transfused blood and reduce the likelihood of transfusion-transmissible infections.
The global market for blood screening is anticipated to experience substantial expansion, propelled by a convergence of factors that emphasize its critical significance in the healthcare industry. A significant factor driving market growth is the escalating global incidence of infectious diseases and chronic conditions. The ongoing development and persistence of these health challenges generate an increased need for precise and effective blood screening technologies, thereby establishing a conducive atmosphere for market expansion. The market is additionally driven by the necessity to guarantee blood safety, specifically during medical procedures and blood transfusions, which encourages the implementation of sophisticated screening methods. In the market for blood screening, the relationship between manufacturers and consumers is distinguished by an emphasis on innovation, dependability, and regulatory compliance. To address emergent infectious threats, optimize operational efficiency, and increase the sensitivity and specificity of screening tests, manufacturers consistently allocate resources toward research and development.
Effective collaboration between manufacturers and regulatory bodies is of utmost importance to navigate the complex realm of compliance and guarantee that screening procedures adhere to stringent criteria for both safety and effectiveness. Furthermore, to promote a holistic approach to public health, manufacturers are actively participating in educational campaigns that aim to enlighten healthcare practitioners and consumers alike regarding the critical nature of blood screening. An emerging trend in the blood screening industry is the increasing prevalence of personalized medicine and precision healthcare. Technological advancements, including Next Generation Sequencing (NGS), facilitate extensive molecular profiling, thereby creating novel opportunities to customize screening methodologies according to the specific requirements of each patient. This phenomenon is consistent with more extensive healthcare endeavors that prioritize personalized and preventative care, thereby creating prospects for market participants to create inventive solutions that accommodate this ever-changing environment.
Supply-side Dynamics
Prominent companies including Abbott Laboratories, Roche Diagnostics, Bio-Rad Laboratories, Grifols, and Ortho Clinical Diagnostics are present in the global blood screening market. These leaders in their field utilize their vast knowledge and skills in the development of sophisticated screening technologies to maintain a dominant position in the market. The United States, in particular, is widely recognized as the dominant region in terms of blood screening technology adoption. The robust regulatory framework and firmly established healthcare infrastructure in North America are factors that contribute to the region's market dominance. European nations, with Germany and the United Kingdom in particular, exert considerable influence on market utilization owing to their resilient healthcare systems.
Prominent entities operating within the blood screening industry are proactively influencing the terrain using ongoing innovation and strategic alliances. For example, Abbott Laboratories is at the forefront of innovation in the field of rapid point-of-care testing solutions, which significantly improve the efficiency and accessibility of blood screening. By concentrating on molecular diagnostics, such as Next Generation Sequencing, Roche Diagnostics is facilitating a paradigm shift in the field of comprehensive blood screening capabilities. The dedication of Bio-Rad Laboratories to research and development is propelling progress in serological testing methodologies. In contrast, Grifols and Ortho Clinical Diagnostics are strengthening their market position on a global scale using acquisitions and partnerships. The constant evolution of technology ensures that the market remains dynamic and adaptable to the changing demands of the healthcare sector through the combined efforts of these dominant actors.
What Technology Will Be Targeted the Most for Installations?
Nucleic Acid Amplification Test to be Dominate owing to their Exceptional Sensitivity and Precision
It is anticipated that the Nucleic Acid Amplification Test (NAT) sector will hold the most significant portion of the market in the blood screening industry. Due to its exceptional sensitivity and precision in identifying viral and bacterial infections, NAT is the method of choice for blood screening applications. The market dominance of NAT is propelled by the demand for accurate and dependable screening methods, particularly in the context of blood safety and transfusion services. It is expected that Next Generation Sequencing (NGS) will witness the most rapid expansion within the blood screening industry. Next-generation sequencing (NGS) provides exceptional capabilities for the concurrent detection of numerous pathogens, thereby furnishing exhaustive and intricate genetic data. With the healthcare sector progressively adopting personalized medicine and requiring more advanced diagnostic methods, next-generation sequencing (NGS) is positioned to experience substantial uptake, propelling its market segment to expand at an accelerated rate. Due to its capacity for comprehensive molecular profiling, this technology is at the forefront of the ever-changing field of blood screening methodologies.
Why is North America Emerging as a Dominating Region?
Sophisticated Technological Capacities And Rigorous Regulatory Frameworks to Promote Growth
It is expected that North America will hold the largest market share in the worldwide blood screening industry. The aforementioned supremacy can be ascribed to the region's firmly established healthcare infrastructure, sophisticated technological capacities, and rigorous regulatory frameworks that advocate for blood safety. The market share is significantly influenced by the United States, primarily because of its high prevalence of chronic diseases, growing consciousness regarding blood safety, and strong demand for advanced diagnostic technologies. Furthermore, significant financial commitments towards research and development, in conjunction with an active stance towards implementing novel screening techniques, serve to reinforce North America's standing as a dominant market participant in the blood screening sector.
What Opportunities Lie in South Asia and the Pacific for Manufacturers?
Incidence of Communicable Diseases and the Expansion of Healthcare Accessibility to Generate Revenue
South Asia and the Pacific are anticipated to witness the most rapid expansion of the worldwide blood screening industry. A burgeoning population, rising healthcare awareness, and increasing investments in healthcare infrastructure all contribute to the region's expansion. Blood screening services are experiencing increased demand in countries such as India, China, and Australia as a result of the rising incidence of communicable diseases, the expansion of healthcare accessibility, and a proactive stance towards blood safety. Furthermore, there is a growing trend towards the implementation of sophisticated technologies, such as point-of-care testing, in this area. This development enables expedited and decentralized blood screening procedures. The region's significance as a pivotal growth center for the worldwide blood screening market is reinforced by endeavors to rectify healthcare inequalities and enhance blood transfusion services, thereby augmenting the potential for market expansion in South Asia & Pacific. In brief, the market share of North America is anticipated to be dominated by its firmly established healthcare ecosystem, whereas the rapid growth of South Asia & Pacific can be attributed to escalating healthcare investments, a sizable and heterogeneous populace, and an expanding recognition of the criticality of blood screening in safeguarding public health and safety.
Prominent entities in the worldwide blood screening industry, including Abbott Laboratories, Roche Diagnostics, Bio-Rad Laboratories, Grifols, and Ortho Clinical Diagnostics, maintain and increase their market presence through the implementation of diverse and comprehensive strategies. An essential approach entails persistent innovation and the advancement of state-of-the-art technologies. An example of a company that prioritizes the development of swift point-of-care testing solutions to improve diagnostic speed and accessibility is Abbott Laboratories. Roche Diagnostics is an industry leader in molecular diagnostics, specializing in Next Generation Sequencing (NGS), which offers exhaustive genetic insights for blood screening. Ongoing progress in enzyme immunoassay (EIA), chemiluminescence immunoassay (CLIA), and nucleic acid testing (NAT) technologies empowers these entities to provide cutting-edge solutions that guarantee the utmost precision in blood screening.
Partnerships and collaborations are indispensable for securing market share. Grifols and Ortho Clinical Diagnostics form strategic alliances to augment their technological capacities and product portfolios. Through strategic partnerships with healthcare providers, research institutions, and other industry frontrunners, these entities acquire valuable resources and knowledge that enhance the progress and implementation of groundbreaking blood screening solutions. Regulatory compliance is of the utmost importance in the context of blood screening and transfusion services, considering the sensitive nature of these services. Major actors make substantial investments to navigate intricate regulatory environments. Prominent industry players such as Abbott Laboratories and Roche Diagnostics comply with rigorous regulatory criteria to guarantee that their products satisfy both international and regional demands. This dedication not only fosters confidence among regulatory entities but also fortifies their standing as dependable and compliant service providers in the marketplace.
New Product
In March 2023, H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio made the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays available for use with the fully automated random-access LUMIPULSE G immunoassay systems official statements of availability. Within 35 minutes, this chemiluminescent enzyme immunoassay (CLEIA) assays enable the quantification of neurofilament light (NfL) in plasma/serum and human cerebrospinal fluid (CSF), respectively.
Market Impact: Fujirebio and H.U. Group Holdings Inc. have introduced Lumipulse G NfL CSF and Lumipulse G NfL Blood assays, which signify a substantial advancement in the worldwide blood screening industry. Specifically developed for utilization with fully automated LUMIPULSE G immunoassay systems, these assays provide an expeditious and effective approach to measuring neurofilament light (NfL) concentrations in human cerebrospinal fluid (CSF) and plasma/serum. This innovation contributes to the advancement of technology in the market by equipping healthcare practitioners with sophisticated tools for screening and monitoring neurodegenerative diseases. As a result, patient care and diagnostic precision are significantly enhanced within an impressively brief span of 35 minutes.
|
Attribute |
Details |
|
Forecast Period |
2023 to 2030 |
|
Historical Data Available for |
2018 to 2022 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Technology:
By Product:
By Region:
To know more about delivery timeline for this report Contact Sales
The market is anticipated to grow at a CAGR of 8.5% during the projected period.
The Blood Screening market was valued at USD 2,227.3 million in 2023.
The United States held the largest market share in 2023.
The prominent players in the market are Abbott, Becton Dickinson, and Company, Bio-Rad Laboratories, Inc., and Hoffman-La Roche Ltd., among others.
The next-generation sequencing segment is expected to grow at the fastest growth during the forecast period.
